Htr1D Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{-
| Attribute | Value |
|---|---|
| Protein Name | 5-HT1D Receptor |
| Gene Symbol | HTR1D |
| UniProt ID | P28221 |
| Molecular Weight | ~41 kDa |
| Subcellular Localization | Plasma membrane |
| Protein Family | 5-HT1 receptor family |
| Structure | 7-transmembrane GPCR |
The 5-HT1D receptor (HTR1D) is a G protein-coupled receptor (GPCR) that binds serotonin (5-hydroxytryptamine) with high affinity and mediates inhibitory neurotransmission in the central and peripheral nervous systems[1]. This receptor belongs to the 5-HT1 family, which includes 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, and 5-HT1F subtypes. HTR1D is characterized by its Gi/o protein coupling, which inhibits adenylate cyclase and reduces intracellular cAMP levels[2]. The receptor is predominantly expressed in the trigeminal ganglion, cranial vasculature, and specific brain regions, making it a crucial target for migraine therapy and neurological research.
The 5-HT1D receptor possesses the classic seven-transmembrane domain structure characteristic of class A GPCRs[3]:
The ligand-binding pocket is formed by residues in:
HTR1D mediates multiple physiological processes through Gi/o protein signaling[4]:
| Region | Expression | Function |
|---|---|---|
| Trigeminal ganglion | Very High | Migraine pathophysiology |
| Dorsal raphe nucleus | High | Mood regulation |
| Cerebral cortex | Moderate | Cognitive processing |
| Hippocampus | Moderate | Memory modulation |
| Basal ganglia | Low-Moderate | Motor control |
HTR1D is a well-established therapeutic target for acute migraine treatment[5]:
HTR1D alterations in AD include:
In PD, HTR1D is involved in:
| Drug | Type | Clinical Use |
|---|---|---|
| Sumatriptan | Agonist | Acute migraine |
| Zolmitriptan | Agonist | Acute migraine |
| Eletriptan | Agonist | Acute migraine |
| Lasmiditan | Agonist | Acute migraine (no vasoconstriction) |
| BRL-15572 | Antagonist | Under investigation |
HTR1D activates multiple downstream cascades[6]:
Current research focuses on:
The study of Htr1D Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Hoyer D, Clarke DE, Fozard JR, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev. 1994;46(2):157-203. PMID:7938165 ↩︎
Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 1999;38(8):1083-1152. PMID:10457221 ↩︎
Saxena A, Villalon CM. 5-HT1D receptors: effect of selective ligands and therapeutic potential. J Serotonin Res. 1995;2(2):77-95. ↩︎
Middlemiss DN, Hutson PH. The 5-HT1B receptors. Ann N Y Acad Sci. 1990;600:132-147. PMID:2252301 ↩︎
Humphrey PP, Feniuk W. Mode of action of the anti-migraine drug sumatriptan (GR43175). Cephalalgia. 1991;11(Suppl 11):9-12. PMID:1790798 ↩︎
Hoyer D, Martin G. 5-HT receptor classification and nomenclature: towards a harmonization with the human genome. Neuropharmacology. 1997;36(4-5):419-428. PMID:9176810 ↩︎